Victoria Socha

DocwireNews

Ipilimumab plus nivolumab is a first-line combination treatment option in patients with metastatic renal cell carcinoma (mRCC). Data from recent studies have demonstrated the efficacy of first-line immune-oncology vascular endothelial growth factor (IO-VEGF) inhibitor combinations. There are limited data on comparative data between those two strategies; the efficacy of subsequent therapies is also unknown.Shaan Dudani, MBChB, Tom Baker Cancer Centre, University of Calgary<a href="https://www.ucalgary.ca/">,</a> Calgary, Alberta, Canada, and colleagues conducted a comparative analysis of the two treatment strategies. They reported results of the analysis during a poster session at the ASCO 2019 Annual Meeting in a poster titled First-line (1L) Immuno-oncology (IO) Combination Therapies in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).The researchers utilized the International Metastatic RCC Consortium (IMDC) data base to compare patients treated with any first-line IO-VEGF combination with those treated with ipilimumab plus nivolumab. To control for imbalances in IMDC risk factors, the researchers used multivariable Cox regression models.A total of 188 patients received first-line IO <a href="https://www.docwirenews.com/latest-nephrology-news/nivolumab-plus-ipilimumab-versus-sunitinib/">combination therapy</a>; of those 113 were treated with IO-VEGF combinations and 75 with ipilimumab plus nivolumab. The two groups were similar in baseline characteristics and IMDC risk factors.Comparing IO-VEGF combinations versus ipilimumab plus nivolumab, first-line response rate (RR) was 33% versus 40%, time to treatment failure (TTF) was 14.3 months (95% confidence interval [CI], 9.2-16.1) versus 10.2 months (95% CI, 6.7-15.1), and median overall survival was not reached [NR] (95% CI, 22.3-NR) versus not reached (95% CI, 35.1-NR). Following adjustment for IMDC risk factors, the hazard ratio for time to treatment failure was 0.71 (95% CI, 0.46-1.12) and the hazard ratio for death was 1.74 (95% CI, 0.82-3.68).There was variation in second-line treatments. Among patients who received subsequent VEGF-based therapy, second-line response rate was lower in the IO-VEFG cohort (n=20) than in the ipilimumab plus nivolumab cohort (n=20): 15% vs 45%; P=.04). There was no significant difference in time to treatment failure between the two cohorts. The use of immune-oncology following IP-VEGF treatment was uncommon; three of five patients had progressive disease as best response; two of five had partial response/stable disease but their first-line IO-VEGF exposure was short (&lt;3 months).&ldquo;There does not appear to be a superior first-line immune-oncology combination strategy in mRCC, as IO-VEGF combinations and ipilimumab plus nivolumab have comparable first-line response rate, time to treatment failure, and overall survival. Most patients received VEGF-based therapy in the second line. In this group, second-line response rage was greater in patients who received ipilimumab plus nivolumab, though there was no difference in second-line time to treatment failure,&rdquo; the researchers said.Source: Dudani S, Graham J, Wells C, et al. First-line (1L) immune-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC). Abstract of a poster presented at the American Society of Clinical Oncology 2019 Annual Meeting, June 3, 2019, Chicago, Illinois.

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

First-line IO Combination Therapies in mRCC

ASCO 2019

Ipilimumab plus nivolumab is a first-line combination treatment option in patients with metastatic renal cell carcinoma (mRCC). Data from recent studies have demonstrated the ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe